|
Today's Headlines
The risks of end stage renal disease, chronic kidney disease, and sustained doubling of serum creatinine concentration are significantly higher in people with at least 1 symptomatic kidney stone episode, according to the results of a study published August 30 in the British Medical Journal. » Full article
|
|
Children with asthma who use glucocorticoid inhalers may grow shorter on average than those who do not use inhaled corticosteroids, according to a study published September 6 in the New England Journal of Medicine. » Full article
|
ADVERTISEMENT
New Drug Price Type Options:
 White Paper
Two new and different methods to ascertain true drug acquisition cost can save money on Rx drug benefits. Read white paper for details and comparison of NADAC and PAC. |
|
Gabapentin may be an effective and well-tolerated treatment for patients with refractory chronic cough, according to a study published August 28 in The Lancet. » Full article
|
|
Biologic response modifiers developed for the treatment of rheumatoid arthritis do not appear to be associated with an increased risk of cancer, according to a study published September 5 in the Journal of the American Medical Association.
» Full article
|
|
CONTINUING EDUCATION
Welcome to a new CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 CPE credits from September 2012-March 2013 with 7 monthly knowledge-based activities. This month, the professional development activity will cover the pathophysiology, diagnosis, screening, and risk factors associated with diabetes mellitus.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.
|
|
EDITOR'S PICK
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by abdominal pain and altered bowel habits with a duration of at least 3 months. IBS is prevalent, expensive to treat, and is associated with significantly impaired health-related quality of life and reduced productivity. » Full article
|
Survey
a) Further broaden the gap between copay dollar value between preferred and non-preferred brand drug tiers.
b) Demand increase formulary rebates requested from manufacturers of preferred products.
c) Implement more aggressive utilization management (PA, Step, Therapeutic Interchange, etc.) to specifically target these products.
d) Enhanced employment of a closed-formulary benefit design.
e) No action, as I don't believe this couponing will have significant effects.
Respond here and see what your colleagues think too.Want to see the results of our last survey regarding preventive services legislation? Click here.
|
|
|
Like
Tweet
